Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients

被引:10
|
作者
Su, An Ping [1 ]
Cao, Shuang Shuang [1 ]
Tian, Bo Le [1 ]
Zhang, Zhao Da [1 ]
Hu, Wei Ming [1 ]
Zhang, Yi [1 ]
Wang, Zheng Liang [1 ]
Babu, Shah Ram [1 ]
Hu, Tao [1 ]
机构
[1] Sichuan Univ, W China Hosp, Dept Hepatobiliopancreat Surg, Chengdu 610041, Sichuan Provinc, Peoples R China
关键词
INSULIN-RESISTANCE; STENT-SHUNT; GLUCOSE; TIPS; HYPERINSULINEMIA; MANAGEMENT; SURVIVAL; INFUSION;
D O I
10.1016/j.clinre.2011.09.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Patients with liver cirrhosis suffer from hyperinsulinemia, hyperglucagonemia and a certain degree of insulin resistance, and portosystemic shunts may be involved in the etiology. A transjugular intrahepatic portosystemic shunt (TIPS) as a treatment for the complications of portal hypertension leads to hemodynamic changes. The objective of the present study is to evaluate whether TIPS can also affect glycometabolism in cirrhosis patients. Methods: Forty-six liver cirrhosis patients (experimental group [EG]) without diabetes who underwent TIPS were evaluated. Portal venous pressure (PVP), cardiac output (CO) and blood flow in the shunt (BFS) were measured or calculated before TIPS, after 15 minutes and, finally, after 90 days. Twenty-five liver cirrhosis patients without diabetes and without TIPS were included as the control group (CG). Oral glucose tolerance tests (OGTTs) were carried out at 0, 1, 7, 30 and 90 days after TIPS or after inclusion in the study. Indices related to glycometabolism and liver function, which included biochemical values, were also investigated. Results: PVP changed immediately from 39.43 +/- 1.29 cmH(2)O to 21.43 +/- 1.42 cmH(2)O and remained stable thereafter. A pronounced increase in CO was observed after TIPS, while BFS did not change significantly. Also, glycosylated hemoglobin A(1c) (HbA(1c)), fasting plasma glucose (FPG), fasting plasma C-peptide (FPC), glucagon-like peptide-1 (GLP-1) and 2-h post-challenge plasma glucose (2hPG) were non significantly increased after the shunt. Statistically significant hyperinsulinemia and hyperglucagonemia persisted for 90 days after TIPS. In addition, TIPS was followed by an increase in insulin resistance (IR) and beta-cell function. Thirty-four patients in the EG and 15 in the CG were diagnosed with diabetes or prediabetes after 90 days. No significant differences in biochemical values were observed 90 days after the shunt. Conclusion: In addition to causing hemodynamic changes, TIPS augments hyperglucagonemia because of increased secretion and decreased clearance of glucagon in the liver, whereas IR deteriorates after the procedure. However, glycemic control does not worsen after TIPS, and the procedure is not associated with a higher risk of diabetes largely because of the simultaneous increase in insulin. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [1] Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and post-transjugular intrahepatic portosystemic shunt complications in 2020
    Horhat, Adelina
    Bureau, Christophe
    Thabut, Dominique
    Rudler, Marika
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2021, 9 (02) : 203 - 208
  • [2] SLEEP DISTURBANCE IN PATIENTS WITH CIRRHOSIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT
    Zhao, Ming
    Luo, Xuefeng
    Wang, Xiaoze
    Yan, Yuling
    GASTROENTEROLOGY, 2024, 166 (05) : S1580 - S1580
  • [3] Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis
    Karasu, Z
    Gurakar, A
    Kerwin, B
    Hulagu, S
    Jazzar, A
    McFadden, R
    Nour, B
    Sebastian, A
    Cassidy, F
    Stokes, K
    Wright, H
    DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (10) : 1971 - 1976
  • [4] Effect of Transjugular Intrahepatic Portosystemic Shunt on Thrombocytopenia Associated with Cirrhosis
    Zeki Karasu
    Ahmet Gurakar
    Barbara Kerwin
    Saadettin Hulagu
    Ahmad Jazzar
    Robert Mcfadden
    Bakr Nour
    Anthony Sebastian
    Francis Cassidy
    Kenneth Stokes
    David Van Thiel
    Harlan Wright
    Digestive Diseases and Sciences, 2000, 45 : 1971 - 1976
  • [5] Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis
    Troels M. Busk
    Søren Møller
    Flemming Bendtsen
    Current Hepatology Reports, 2017, 16 (3) : 250 - 257
  • [6] SLEEP DISTURBANCE IN PATIENTS WITH CIRRHOSIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT
    Zhao, Ming
    Luo, Xuefeng
    Wang, Xiaoze
    Yan, Yuling
    HEPATOLOGY, 2023, 78 : S1411 - S1411
  • [7] Sleep disturbance in patients with cirrhosis and transjugular intrahepatic portosystemic shunt
    Zhao, Ming
    Yan, Yuling
    Wang, Xiaoze
    Liu, Bangxi
    Luo, Xuefeng
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [8] Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt
    Yang, Chongtu
    Liu, Jiacheng
    Shi, Qin
    Huang, Songjiang
    Zhou, Chen
    Wang, Yingliang
    Li, Tongqiang
    Chen, Yang
    Xiong, Bin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (10) : 2893 - 2902
  • [9] The Effect of Transjugular Intrahepatic Portosystemic Shunt on Renal Function in Patients With Liver Cirrhosis
    Aggarwal, Ashish
    Mitchell, Justin E.
    Hanouneh, Ibrahim A.
    Atreja, Ashish
    Zein, Nizar N.
    GASTROENTEROLOGY, 2011, 140 (05) : S958 - S958
  • [10] TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT IN ELDERLY PATIENTS WITH CIRRHOSIS: A MUTICENTRIC STUDY
    Vizzutti, Francesco
    Saltini, Dario
    Celsa, Ciro
    Bianchini, Marcello
    Nardelli, Silvia
    Senzolo, Marco
    Miraglia, Roberto
    Calvaruso, Vincenza
    Roccarina, Davide
    Gitto, Stefano
    Zanetto, Alberto
    Caporali, Cristian
    Fanelli, Fabrizio
    Maruzzelli, Luigi
    Enea, Marco
    Battaglia, Salvatore
    Federica, Indulti
    Colecchia, Antonio
    Burra, Patrizia
    Riggio, Oliviero
    Villa, Erica
    Marra, Fabio
    Camma, Calogero
    Schepis, Filippo
    HEPATOLOGY, 2022, 76 : S1137 - S1138